TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Status:
Completed
Trial end date:
2018-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the superiority of CHF 5993 200/6/12.5 µg pMDI
(fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus
glycopyrronium bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine
beclometasone dipropionate plus formoterol fumarate) and to compare the effect of CHF 5993
200/6/12.5 µg pMDI vs CHF 5993 200/6/12.5 µg plus open-label Tiotropium 2.5µg, in terms of
lung functions parameters and rate of exacerbations, as well as to assess its safety and some
health economics outcomes.